Newsletter Tool

To view this email as a web page, click here

Today's Rundown

First-to-market Pfizer expects a whopping $15B from its COVID-19 shot in 2021
States 'need more supply' of COVID-19 vaccine amid push to grant more shots
Amid supply snafu, new data show AstraZeneca's COVID-19 shot is more effective with doses 12 weeks apart
Ellume nets $232M government contract to produce COVID-19 home tests in U.S.
HCA beat Wall Street expectations with $3.8B profit in year marked by roller coaster volumes, pandemic costs
COVID-19 tracker: Moderna aims to fit more doses into shot vials
UPDATED Coronavirus tracker: Biden admin to begin direct vaccine shipments to pharmacies
CDMO Catalent trumpets biologics windfall courtesy of COVID-19
Pharma PR in a pandemic? Speed, clarity and accuracy count during unintentional stress test

Featured Story

First-to-market Pfizer expects a whopping $15B from its COVID-19 shot in 2021

By Eric Sagonowsky

More and more COVID-19 vaccines are nearing the market, but mRNA shots from Pfizer and Moderna are still working off a head start in the global rollout. Now, Pfizer has revealed just what that head start could be worth this year.

States 'need more supply' of COVID-19 vaccine amid push to grant more shots

By Robert King

Several states told a congressional panel the have the capacity to deliver more COVID-19 doses than they are getting from the federal government.

Amid supply snafu, new data show AstraZeneca's COVID-19 shot is more effective with doses 12 weeks apart

By Eric Sagonowsky

While supply constraints have hung over the rollout of the AstraZeneca COVID-19 vaccine in Europe, last week, the company's CEO Pascal Soriot offered one way that officials could make the most out of available doses. And now more data support that approach—in fact, it might even be better.

Ellume nets $232M government contract to produce COVID-19 home tests in U.S.

By Conor Hale

Australian COVID-19 diagnostic maker Ellume has secured a $231.8 million contract from the Biden administration to establish its first production facility in the U.S., and deliver 8.5 million of its at-home tests.

HCA beat Wall Street expectations with $3.8B profit in year marked by roller coaster volumes, pandemic costs

By Tina Reed

The last year has been a roller coaster for hospitals across the country when it came to skyrocketing costs and fluctuating patient volumes. But for HCA Healthcare, it was a good year—financially speaking—with the Nashville, Tennessee-based hospital giant posting an uptick in profits for both the fourth quarter and the year.

COVID-19 tracker: Moderna aims to fit more doses into shot vials

By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale

Moderna wants to fit more doses into its vaccine vials. Catalent's biologics revenue soared in the second quarter, thanks to a slew of COVID manufacturing projects. Ellume nabbed a $232 government contract to produce at-home COVID tests in the U.S. Plus, the CDC is ramping up efforts to track virus variants.

UPDATED Coronavirus tracker: Biden admin to begin direct vaccine shipments to pharmacies

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

CDMO Catalent trumpets biologics windfall courtesy of COVID-19

By Fraiser Kansteiner

Buoyed by production contracts with major COVID vaccine players Moderna, Johnson & Johnson and AstraZeneca, Catalent saw its biologics revenues hit $403.9 million in the second quarter its 2021 fiscal year. That's a whopping 76% increase in constant currencies over the same quarter last year.

Pharma PR in a pandemic? Speed, clarity and accuracy count during unintentional stress test

By Beth Snyder Bulik

The COVID-19 pandemic has put pharma and healthcare public relations to the test, challenging communications teams in ways they couldn’t have anticipated. Now, after almost a year of racing to place accurate and clear messages in the market, Evoke Kyne—like many others—is emerging from the gauntlet with new hires and new business wins.

COVID-19 Tracker